Imlifidase
- Generic Name
- Imlifidase
- Brand Names
- Idefirix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1947415-68-0
- Unique Ingredient Identifier
- UVJ7NL8S2P
- Background
Chronic kidney disease (CKD) is a progressive and irreversible disease that represents a significant burden for both the individual and healthcare system at large. Currently available treatments for end-stage renal disease are limited to dialysis and renal transplantation, with the former associated with significant costs and lower quality of life.
...
- Indication
Imlifidase is indicated for desensitization of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. The treatment is reserved for patients unlikely to receive a transplant under the available kidney allocation system including prioritization programs for highly sensitized patients.
- Associated Conditions
- -
- Associated Therapies
- Desensitization
Cyrus Biotechnology Announces Potent in vivo Redosability of an Engineered IdeS
Cyrus Biotechnology Congratulates David Baker, 2024 Nobel Laureate in Chemistry and ...
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.